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ABSTRACT 
Campylobacter jejuni clone SA has emerged as the predominant cause of 
Campylobacter-associated ovine abortion in the U.S., and this clone is highly pathogenic in 
pregnant sheep and guinea pigs.  To induce abortion, orally ingested Campylobacter must be 
able to translocate across the intestinal epithelium and spread systemically.  To understand 
the pathogenic mechanisms and immune protection of C. jejuni-induced abortion, it is 
necessary to develop a cost-effective animal model to evaluate systemic infection induced by 
this pathogenic clone.  In this study, two different breeds of female mice (BALB/c and CD-1) 
were orally inoculated with C. jejuni IA3902, a clinical clone SA isolate whose complete 
genome sequence has been determined, to evaluate the induction of bacteremia and hepatic 
infection.  Our results revealed that CD-1 mice were more susceptible than BALB/c mice to 
infection by IA3902.  In CD-1 mice, C. jejuni IA3902 induced bacteremia and hepatic 
infection within 1 hour after oral inoculation, and bacteremia peaked at 8 and/or 12 hours 
after inoculation.  Compared with IA3902, the magnitude and duration of bacteremia and 
hepatic infection induced by C. jejuni strains NCTC 11168 and 81-176 were significantly 
less prominent, indicating that IA3902 is more virulent than the other strains tested with 
regard to systemic spread.  Mutagenesis in IA3902 showed that the loss of the capsule 
(ΔkpsS) completely prevented the organism from causing bacteremia and hepatic infection, 
while the loss of pVir plasmid did not affect systemic spread.  These findings indicate that 
the CD-1 mouse model is suitable for examining critical steps of Campylobacter 
pathogenesis and identify the capsule as a key virulence factor of this pathogenic organism to 
induce bacteremia.  
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CHAPTER 1. GENERAL INTRODUCTION 
 
Introduction 
Campylobacter jejuni has long been recognized as a cause of bacterial foodborne 
illness, and it remains the most prevalent bacterial foodborne pathogen in the industrial world 
to date (38).  In 2009, according to the Centers for Disease Control and Prevention (CDC) 
FoodNet surveillance program, Campylobacter was identified as the second leading cause of 
laboratory-confirmed bacterial foodborne disease (13.02 per 100,000 people) behind 
Salmonella (15.19 per 100, 000 people) in the United States (32).  In fact, the latest estimate 
from the CDC indicated 800,000 cases of campylobacteriosis occur annually in the United 
States (32).   
Several factors have been found to influence Campylobacter infections, including age 
(higher incidence in children under the age of 5), the season (more prevalent during summer 
months), the strain variation (certain strains are less virulent than others), and demographic 
factors (social economic status), all of which contribute to the morbidity and mortality 
worldwide (129) .  Campylobacter is highly infectious and infective doses as low as 500 to 
800 CFU have been reported in human patients (66).  The organism is transmitted to humans 
through a variety of sources, such as contact with infected pets or consumption of 
contaminated milk or water (80).  However, the most frequent source of C. jejuni infection is 
contaminated, undercooked poultry meat (41,44,50).  In humans, C. jejuni colonizes the 
intestinal epithelium and often causes a mild, watery diarrhea to severe, bloody diarrhea.  
Campylobacter enteritis may occasionally lead to the development of immune-mediated 
neurological sequelae known as Guillain-Barré syndrome (GBS)(159).   
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Campylobacter spp. are widespread among livestock and poultry, usually colonizing 
the intestines without causing clinical diseases, however, they may be associated with 
important illnesses, including infertility and abortion in ruminants (43,128,133).  
Campylobacter-associated abortions in domestic ruminants are an important management 
problem in agriculture, and can be a major economic loss to producers (133).  Campylobacter 
infection is one of the most prevalent causes of ovine abortion in the United States and 
worldwide, with an overall abortion rate of 5 to 50% (average, 23.2%) in affected flocks 
(128,133).  In susceptible pregnant ewes, initial oral exposure may be followed by 
bacteremia with subsequent placentitis, fetal infection, and abortion, which usually occurs in 
the last trimester of pregnancy (128,133).  Effective intervention strategies to mitigate sheep 
abortion caused by Campylobacter have been hindered mainly because of gaps in our 
understanding of its virulence mechanisms, the lack of an adequate animal model for the 
disease, and a growing incidence of antibiotic resistance strains or vaccine failures (38).    
Despite being a major cause of enteric disease in humans and infectious abortion in 
animals, significant progress has been made during the last decade in understanding the 
pathobiology of C. jejuni.  Specific virulence mechanisms for Campylobacter remain poorly 
understood, in part due to the lack of efficient genetic tools and disease-duplicating animal 
model systems.  A few putative virulence factors have been discovered, including flagella-
mediated motility, bacterial adherence to intestinal mucosa, the ability to invade enterocytes, 
the ability to produce toxins, capsular polysaccharide and the pVir plasmid (7,38).  For C. 
jejuni to reach the gastrointestinal tract it must survive the stresses encountered in the 
stomach and small intestine due to gastric acid and bile salts, respectively.  It is known that 
flagellar motility is required for colonization of the mucosal layer, where the organism can 
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adhere to the host’s intestinal cell surface and produce cytotoxins.  In most cases, C. jejuni 
only causes a localized infection in the gut and does not spread systemically, however highly 
virulent C. jejuni strains may be able to penetrate the epithelial barrier and spread to 
extraintestinal sites, such as the liver, gallbladder, pancreas, uterus, and fetal tissues (135). 
Ongoing work at Iowa State University has demonstrated that a single clone of C. 
jejuni, named clone SA (for sheep abortion), has emerged in recent years as the predominant 
cause of Campylobacter-associated sheep abortions and has also been identified to be a cause 
of bovine and caprine abortions in the United States (30,119,128).  The exact mechanisms 
that this pathogenic clone uses to cause abortions remain largely unknown.  Using an 
established pregnant guinea pig model, we demonstrated the high virulence property of C. 
jejuni clone SA in inducing abortion compared with other C. jejuni strains (29,30).  Although 
clone SA is highly abortifacient in sheep and guinea pigs, bacterial factors involved in this 
process are largely unknown.  To begin to understand how clone SA causes abortion, we 
have recently obtained the complete genome sequence of a clinical isolate of clone SA, 
IA3902 (GenBank accession no: CP001876.1 and CP001877.1).  Although comparative 
genomics analyses indicated presence of a few genes that are uniquely associated with this 
clone SA strain, its genome shows overall remarkable similarity to those of non-abortifacient 
isolates, implicating that it must possess unique and complex virulence attributes allowing it 
to be a successful invader of the fetoplacental unit. 
To study pathogenesis in detail, an efficient animal model is needed to assess 
invasion of the intestine and the subsequent induction of bacteremia.  Although the pregnant 
guinea pig model is appropriate for investigating Campylobacter-associated abortion in 
sheep, it is cost-prohibitive and presents ethical concerns, as it involves pregnant animals.  
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On the other hand, mouse models for Campylobacter infections have shown that bacteremia 
is a common phenotype for invasiveness and can be consistently measured with this model 
system (22,24,113,115,149).  Here, we report recent progress in developing a mouse model 
suitable for examining critical steps of C. jejuni pathogenesis and identify the capsule as a 
key virulence factor of this pathogenic organism’s ability to induce bacteremia.  The 
outcomes of this study improve our understanding of pathogenesis of abortion caused by C. 
jejuni clone SA, and aid in the development of means to control this major disease in sheep.    
 
Thesis Organization 
This thesis consists of three chapters.  The first chapter is a literature review that 
includes a general overview of Campylobacter (mainly C. jejuni) and Campylobacter 
abortion, key elements for pathogenesis, and current animal models.  The second chapter 
describes the development of a mouse model for Campylobacter-induced bacteremia and the 
investigations on virulence traits of clone SA.  The third chapter is a general conclusion.  The 
references cited throughout the text are located immediately after each chapter.   
 
Literature Review 
 
Taxonomy and biology 
Although McFadyean and Stockman isolated the first Vibrio-like bacteria from 
aborted ovine fetuses in 1913 (147), it is believed that the first observation of Campylobacter 
occurred in 1886 by Theodor Escherich, who described non-culturable spiral-shaped bacteria 
(92,147,148).  In the following decades, several spiral-shaped organisms were detected 
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primarily by veterinarians, with these ultimately being designated as Vibrio species.  In 1927, 
Smith and Orcutt named a group of bacteria isolated from the feces of cattle with diarrhea as 
Vibrio jejuni (129).  Similarly, in 1944, Doyle isolated yet another vibrio from feces of pigs 
with diarrhea and classified them as Vibrio coli (92,129,147).   
As a result of their low G + C content in chromosomal DNA, their microaerophilic 
growth requirements and their nonfermentive metabolism, Sebald and Véron proposed the 
genus Campylobacter in 1963, distinguishing them from the “true” Vibrio species.  Since 
then, advances in methods for selective isolation of Campylobacter and taxonomic tools such 
as molecular methods have resulted in many more species being added to the genus, albeit 
with some misclassifications.  The family Campylobacteraceae consists of the genera 
Campylobacter, Arcobacter, Sulfurospirillum and Bacteroides ureolyticus, all of which occur 
primarily as commensals in humans and domestic animals (147).  The genus Campylobacter 
is currently comprised of 14 phenotypically and genotypically heterogeneous species: C. 
jejuni, C. coli, C. lari, C. upsaliensis, C. helveticus, C. fetus, C. hyointestinalis, C. mucosalis, 
C. concisus, C. curvus, C. showae, C. rectus, C. sputorum and C. gracilis.   
Campylobacter species are small (~0.5 µm wide and ~3 µm long), Gram-negative, 
spiral or curve shaped rods.  Most species possess a single, unsheathed polar flagellum that is 
present at one or both poles, giving the cell rapid motility in viscous environments, such as 
the gastrointestinal mucosal layer (52).  Some species are non-motile (C. gracilis) or have 
multiple flagella (C. showae).  Campylobacter species are microaerophilic, growing best in 
an atmosphere with low oxygen tension (5% O2, 10% CO2 and 85% N2) (51).  The optimum 
growth temperature for Campylobacter lies between 37 and 42°C.  Typical biochemical 
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characteristics include the presence of oxidase activity and hippurate hydrolysis (only C. 
jejuni).  Campylobacter spp. are fastidious organisms, which do not readily ferment 
carbohydrates, but are thought to primarily use amino acids as their carbon source (147).   
 
Genomic Characteristics 
Since most of the research on Campylobacter has been focused on C. jejuni, this 
literature review will mainly focus on C. jejuni as an important pathogen.  C. jejuni has a 
relatively small circular genome between 1.6 and 1.8 megabases with a rather low G + C 
content of 30% (52).  It is naturally competent, meaning that it can take up DNA from the 
environment, giving way to more genetic diversity, including antibiotic resistance (159).  
Since the publication of the complete genomic sequence of Campylobacter jejuni NCTC 
11168 in February 2000 (114), mounting evidence suggests that C. jejuni strains are 
genomically diverse (42,99,114).  Several studies have been aimed at describing this 
diversity.  For example, unique genomic DNA sequences of Campylobacter jejuni 81-176 
were identified by comparison with C. jejuni NCTC 11168 (121).  C. jejuni 81-176 carries 
two large plasmids, named pVir and pTet (13,16) while 11168 does not possess either one of 
the plasmids (15).  Recently, we discovered a highly virulent C. jejuni clone (clone SA for 
sheep abortion) that is responsible for the majority of ovine abortions in the United States 
(128), and determined the complete genome sequence (GenBank accession no: CP001876.1 
and CP001877.1) of a clinical isolate of clone SA (IA3902).  Comparative genomics with the 
non-abortifacient NCTC 11168 indicated the presence of a number of genes that are uniquely 
associated with this strain (Q. Zhang laboratory, unpublished data).  These genomic 
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differences may help explain the observed difference in virulence between clone SA and 
other strains of C. jejuni.  
 
Pathogenesis 
As a zoonotic pathogen, Campylobacter colonizes the gastrointestinal tracts of a 
variety of animal hosts, either as a commensal or as a pathogen (80).  C. jejuni is an enteric 
organism and is transmitted by the fecal-oral route.  To establish an infection, C. jejuni must 
first survive the acidic conditions in the stomach, and then colonize the large intestine 
(120,131,159).  Colonization of the gut mucosa depends on flagellar motility and corkscrew 
morphology of the organism, and its ability to adhere to the mucosal layer (131,159).  Once 
established, it activates other virulence factors and toxins to cause inflammation and 
epithelial damage with fluid secretion (152).  However, our understanding of these virulence 
processes in Campylobacter pathogenesis is poorly developed compared with other enteric 
pathogens.    
Despite our limited knowledge of the pathogenic mechanisms of this organism, 
flagella-mediated motility, bacterial adherence to the intestinal mucosa, invasiveness and the 
ability to produce toxins have been identified as virulence factors allowing C. jejuni to 
colonize the host (7,38,129,146).  Campylobacter also possesses mechanisms for adaptation 
to various environmental conditions such as iron limitation, temperature fluctuations, and 
oxygen rich atmosphere (53,58).  
Although various virulence factors have been implicated (15,19,96), the precise 
mechanism(s) contributing to the pathogenesis of Campylobacter spp. have yet to be 
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elucidated, partly because of the lack of a suitable animal model and partly due to difficulties 
in genetic manipulation of this organism (146). 
 
a) Flagella 
C. jejuni flagella and flagellar motility are vital to many aspects of C. jejuni biology, 
including host colonization, host cell invasion and secretion.  Flagella are involved in auto-
agglutination (103) and biofilm formation (85,86).  The role of motility in the virulence of C. 
jejuni was established by use of isogenic non-flagellated mutants unable to colonize the 
intestine of experimental animals (38,157).  Furthermore, Wassenaar and Blaser (153) 
demonstrated that aflagellated C. jejuni mutants show a significant reduction of 
internalization by host cells, suggesting the importance of flagella in invasion.   Structurally, 
the flagellar filament consists of flagellin subunits encoded by two tandem genes, flaA (major 
subunit) and flaB (minor subunit) (112).  A two-component system comprised of the sensor 
FlgS and the response regulator FlgR is central for the regulation of the Campylobacter 
flagellum (38).  Additional regulation involves fliA, rpoN, and the housekeeping gene rpoD 
for motility, protein secretion and invasion (31,69,70,77,156).  Two proteins, FlgP and FlgQ, 
were shown to be essential for flagellar motility in C. jejuni, however, their functional roles 
remain unclear (137).  Homologs of other important flagellar gene regulators like FlhC and 
FlhD, found in other bacterial species have not been identified in the C. jejuni genome (114).  
In addition to agglutination, attachment and biofilm formation, bacterial flagella also enable 
chemotaxis, a behavior that plays an important role in both the commensal and pathogenic 
lifestyle of C. jejuni (159).  Together, these data demonstrate that flagella and associated 
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components are crucial factors for the initial interaction of C. jejuni with its host, leading to 
colonization of the intestine.   
 
b) Lipooligosaccharide and capsule 
Surface polysaccharides represent the predominant structures on all bacterial cell 
surfaces, and they are often important in the interactions between pathogens, their hosts and 
the environment (57,62).  C. jejuni is polysaccharide-rich, harboring four well-defined 
carbohydrate biosynthetic loci encoding proteins responsible for biogenesis of the 
lipooligosaccharide (LOS), capsular polysaccharide (CPS), O-linked flagellar sugars and N-
linked protein glycans.  The LOS and CPS produced by different strains of C. jejuni are 
structurally complex and highly variable.  Many genes in these hypervariable regions are also 
subject to phase variation, further producing genetic and phenotypic diversity and 
confounding immune system responses to C. jejuni infection (108).   
As in other enteric pathogens, C. jejuni expresses a phase-variable outer LOS core 
capable of mimicking human antigens.  C. jejuni is one of a few bacteria that are capable of 
the endogenous synthesis of sialic acid for incorporation into these ganglioside-like LOS 
cores (65).  The LOS molecule is comprised of two components: a lipid A anchor and an 
oligosaccharide consisting of a conserved inner core and a variable outer core, therefore it is 
referred to as LOS, because it lacks the O-antigen found in lipopolysaccharides (59,71,88).  
LOS is an important factor in Campylobacter pathogenesis.  Currently, the best-characterized 
contribution of the C. jejuni LOS to human disease is its relationship to the debilitating 
neuropathy Guillain-Barre syndrome, GBS (106,142), in which the LOS structures mimic the 
human gangliosides on peripheral nerves.  Depending on phase variation of the cgtA gene, 
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the 81-176 LOS can mimic human GM2, GM3, CD1b and GD2 gangliosides (57).  
Numerous studies have shown that various LOS mutants are surprisingly sensitive to certain 
antimicrobial substances (79,87,100,101).  Despite its contribution to chronic sequelae such 
as GBS, no direct pathogenic role for the LOS has been definitively identified.   
The capsular polysaccharide (CPS) is the outermost structure on the bacterial cell, 
and possibly plays a key role in the interaction between the pathogen, host and environment 
(142).  Generally, CPS is thought to be important for bacterial survival and persistence in the 
environment and often contributes to pathogenesis (124).  CPS of C. jejuni remained elusive 
until the sequencing of NCTC 11168 revealed a set of genes that are homologous to the type-
II and type-III capsule transport genes of the Enterobacteriaceae (114).  For C. jejuni, the 
CPS is considered to be an important virulence factor based on its involvement in epithelial 
cell adherence, invasion and serum resistance (14,71).  Encapsulated bacteria thwart the 
antibacterial effect of complement by preventing deposition of the host membrane attack 
complex on bacterial membranes (104).  Mutation in the CPS transporter gene, kpsM, results 
in the loss of the capsule, and was found to abolish colonization of chickens (14,84),while 
mutants of systemic strains (C. jejuni 84-19 and 84-25) were >1,000-fold more sensitive to 
complement-mediated killing compared to their respective wild-type strains (90).  A C. jejuni 
mutant for the kpsE gene, which is unable to express any capsular polysaccharide, was not 
hampered in its ability to colonize the chicken intestinal tract, but the number of bacteria 
recovered from the cecum and colon were lowered compared to the control (12).  The CPS is 
phase variable in expression, presumably due to slip-strand mispairing occurring in genes 
essential for CPS synthesis, a mechanism of variation that is common in C. jejuni 
(63,114,142).  The high degree of variability of CPS genes is consistent with CPS being the 
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major serodeterminant of the Penner or heat-stable (HS) serotyping scheme (88).  However, it 
is not known whether differences in sugar composition of the capsule among strains affect 
virulence or whether the phase-variable modifications have a role in pathogenesis or 
interactions with bacteriophages (36).   
 
c) Cytolethal distending toxin 
A variety of toxic activities have been attributed to C. jejuni.  However, cytolethal 
distending toxin (CDT) is the only verified Campylobacter toxin identified.  It is produced by 
a number of Campylobacter spp. including: C. jejuni, C. lari, C. coli, C. fetus and C. 
upsaliensis (38,83).  It has been described as an important virulence factor of this pathogen 
(6).  Significant progress has been made in the past several years that have led to a rapid 
advancement of our understanding of the role of CDT in pathogenesis (14,72,88,89).  CDT 
holotoxin is composed of three subunits encoded by the cdtA, cdtB and cdtC genes (118), and 
causes eukaryotic cells to arrest in the G2/M phase of the cell cycle preventing them from 
entering mitosis and consequently leading to cell death (54,118,162).  It is now clear that 
CdtB is the active moiety of the Cdt ABC complex.  It appears that CdtA and CdtC interact 
with CdtB to form a tripartite CDT holotoxin necessary for the delivery of the enzymatically 
active subunit, CdtB (97).  After that, the CdtB active subunit, which has DNaseI-like 
activity, induces host DNA damage by breaking its double strand (54).  Wild-type C. jejuni 
strain NCTC 11168 produces more toxin and is highly invasive in SCID mouse tissue 
compared to isogenic cdtB mutants, which are unable to produce noticeable amounts of toxin 
(38); similarly, isogenic cdtB mutants of C. jejuni strain  81-176 produce remarkably reduced 
levels of CDT (123).  It is not clear yet what role CDT plays in infection in vivo.  However, it 
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may contribute to the invasiveness and modulation of the immune response rather than 
directly to inducing diarrhea (123). 
 
d) Adhesion and invasion 
Many studies have shown that C. jejuni requires adhesion and binding factors to 
colonize hosts. These experiments have led to the identification of some putative adhesins or 
binding factors of C. jejuni including fibronenctin-binding outer membrane protein CadF 
(94), the periplasmic binding protein PEB1 (116), the autotransporter CapA and the surface-
exposed lipoprotein JlpA (81).  CadF is an outer membrane protein (OMP) expressed in all 
C. jejuni and C. coli strains and mediates cell adhesion by binding to the cell matrix protein, 
fibronectin (38).  CadF is required for maximal binding and invasion by C. jejuni in vitro, 
and cadF mutants are greatly reduced in chick colonization compared with the wild-type 
(105,163).  PEB1 is an adhesin, and also functions as the periplasmic-binding protein 
component of amino acid ABC transporters (116).  PEB1 binds to both aspartate and 
glutamate, and peb1 mutants cannot grow if these amino acids are the major carbon source 
(98).  Thus, the PEB1 transport system appears to have an important role in utilization of 
aspartate and glutamate, however, its function in vivo as an adhesin in C. jejuni is unknown.  
JlpA is a surface-exposed lipoprotein that is crucial for the binding to host epithelial cells 
(81).  One study indicated that JlpA interacts with Hsp90α, triggering signaling pathways that 
activate NF-κB and p38 MAP kinase, both of which are components involved in host 
proinflammatory responses to infections (82).  CapA is another autotransporter lipoprotein 
that has been identified to adhere to human and chicken epithelial cells (8).   
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Cellular invasion is an important pathogenic mechanism of C. jejuni.  The invasion of 
epithelial cell in vivo results in cellular damage and function loss, which leads to stimulation 
of host inflammatory responses and diarrhea (153).  Furthermore, it has been observed that 
diarrheal disease is correlated with the invasiveness of C. jejuni (127).  Similarly, numerous 
studies have established that early mucosal damage is a result of invasion of C. jejuni in the 
colonic epithelial cells (49,74,155), ultimately leading to the conclusion that the invasive 
capability of this organism is an important pathogenic factor.  However, different strains of 
C. jejuni vary in their ability to invade.    
Many invasive pathogens subvert host cytoskeletal structures as part of the 
pathogenic process.  The highly invasive C. jejuni 81-176 demonstrated microtubule-
dependent invasion, and appears to rely on microtubule motors for uptake and intracellular 
motility (25,73).  However, in rabbit intestinal models, C. jejuni selectively associates with 
M cells (48,151), suggesting that this cell type may be an important port of entry.  The 
mechanism starts with the efficient migration of the pathogen (neither strain- nor cell type-
specific) into the subcellular space, followed by a rapid and highly efficient bacterial 
invasion at the basal cell side (145).  Regardless, most C. jejuni strains exhibit 
microfilament-dependent or microfilament/microtubule-dependent invasiveness (20). 
 
Animal Models of Campylobacter jejuni Infections 
 Despite its obvious global importance, relatively little is known regarding 
mechanisms of C. jejuni pathogenesis and host responses to infection.  Many studies have 
sought to establish animal models for study of C. jejuni colonization and gastroenteritis, but 
the lack of high-resolution, facile and reproducible models for studying infection in vivo has 
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clearly hampered progress in this area (33).  Newborn pigs, weanling ferrets, gnotobiotic 
canine pups, and nonhuman primates have been inoculated experimentally with C. jejuni by 
various routes to mimic the course of infection, however, these models suffered from high 
costs, difficulties in animal handling and availability, lack of reproducibility, or inadequate 
biological characterization (11,17,18,33,126,158,160).  Although the chick model allows to 
us investigate colonization and transmission, disease-defining diarrhea is absent, since C. 
jejuni appears to be a commensal organism in this animal.  Regardless, significant progress 
has been made with these models to understand pathogenic mechanisms of C. jejuni.   
 Reliable murine models of C. jejuni infection overcome some of these limitations, 
and offer the advantage of an immune system that is well characterized and has been used 
extensively.  Other advantages are the animals’ small size, wide availability, inexpensive 
housing costs, defined microbial flora, and amenability to manipulation.  A number of 
investigators have shown that oral dosing of C. jejuni in mice of different strains, both inbred 
and outbred, results in intestinal colonization and in some cases bacteremia, but the organism 
does not usually cause clinical diarrhea (2,22,138).  The mouse model also highlighted the 
essential nature of the flagella in colonization of the intestinal mucosa (2,40,111), as well as 
the importance of peb1A in C. jejuni adhesion (117).       
Furthermore, intraperitoneal (IP) inoculation of pregnant guinea pigs has been used as 
a method to evaluate the pathogenicity of Campylobacter spp. (141,143) and to assess the 
efficacy of vaccines (26-28).  Their small size, ease of housing, and relatively short duration 
of gestation make guinea pigs a desirable animal for use in studying Campylobacter-induced 
abortion, particularly when compared with the use of sheep or goats, which are the species 
most commonly affected in nature.  IP inoculation is not the best method for evaluating 
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Campylobacter pathogenesis of septic abortions, because it avoids the critical steps required 
for abortion (intestinal colonization and bacterial invasion).  A recent study (30), reported 
that oral inoculation of a highly virulent C. jejuni strain (clone SA) was effective in inducing 
abortion in pregnant guinea pigs. 
 
Clinical aspects of Campylobacter disease 
a) Campylobacteriosis in humans 
Campylobacter jejuni infection is one of the most commonly identified bacterial 
causes of acute gastroenteritis worldwide (5).  The clinical presentation of patients with 
Campylobacter infection differs between developing and industrialized countries.   In 
developing countries, C. jejuni infection is milder than in developed countries.   Infection can 
be asymptomatic or there may be mild non-inflammatory diarrhea, predominantly affecting 
young children (37).  In the developed world, Campylobacteriosis manifests with abdominal 
pain, diarrhea and fever, which is typically self-limiting (159).  Affected individuals 
experience varying degrees of diarrhea, which may range from a few loose stools to profuse 
watery diarrhea causing dehydration or less often bloody diarrhea with mucus.  The 
incubation period that precedes the development of acute diarrhea is 2-5 days, and although 
the disease is typically resolved in one week, symptoms can last up to two weeks.  Although 
a large proportion of the patients feel nauseous, only about 15% of patients vomit (131).  In 
30% of patients, the disease does not start with diarrhea but with a prodrome of influenza 
virus-like symptoms such as fever, headache, dizziness, and myalgia, indicating that there is 
some systemic, probably immune-mediated, effect of local infection (78,154).  Variations in 
16 
 
bacterial virulence or host immune response each may play a role in these different 
phenotypic expressions of the disease (37,91).   
While Campylobacter enteritis is usually self-limiting, some individuals develop 
sequelae after the acute phase.  Approximately 1 in 1,000 infected individuals develops 
Guillain-Barré syndrome (GBS), a serious autoimmune-mediated neurological disorder that 
can cause symptoms ranging from weakness of extremities to complete paralysis and 
respiratory insufficiency (78).  Molecular mimicry between peripheral nerve glycolipids or 
myelin proteins and structures on the lipopolysaccharides of some Campylobacter strains 
likely plays a role in the pathogenesis of Campylobacter-induced GBS (5,161). 
 
b) Campylobacter in Sheep 
Campylobacter infection is one of the most prevalent causes of ovine abortion in the 
United States and worldwide (128).  Campylobacter species can be carried in the intestines 
and gall bladder of healthy sheep without causing clinical diseases (3,102,128,139).  
However, highly virulent C. jejuni strains can invade into circulation and cause systemic 
infections (135).  In susceptible pregnant ewes, initial exposure may be followed by intestinal 
invasion and bacteremia with subsequent placentitis, fetal infection, and abortion, which 
usually occurs in the last trimester of pregnancy (35,130,133,135).  During the initial period 
of infection, ewes usually do not show any clinical signs of disease; however, occasionally 
ewes die due to uterine sepsis and septicemia if the fetus dies and is retained in utero 
(128,133).  If the onset of infection is delayed closer to term, lambs are born weak and 
typically do not survive.  Gross lesions in aborted ewes include thickened uterine walls with 
edema, swollen caruncles covered with exudate and placentas with mottled swollen 
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cotyledons (68).   Aborted fetuses can be mildly to severely autolyzed and commonly have 
serosanguinous fluid in the abdomen and thorax and less often, focal liver necrosis 
(68,93,128,133).  Histologically, the aborted placentas often have the signs of acute 
suppurative placentitis with congestion and necrosis of cotyledons and trophoblasts can be 
distended with intracytoplasmic organisms that can be stained with Giemsa stain (68,93).  A 
mild to moderate suppurative fetal bronchopneumonia typically is identified.  Less 
consistently, the livers of aborted fetuses have multifocal areas of necrosis surrounded by a 
thin to moderate infiltrate of neutrophils. 
 
c) Bacteremia 
In immunocompetent individuals, disease is usually restricted to the intestine, 
although bacteremia and systemic infection have been observed.  Bacteremia resulting from 
Campylobacteriosis is uncommon and transient in immunocompetent people (134).  
Bacteremia is more common in patients ≥65 years of age with a C. jejuni infection.  Highly 
virulent C. jejuni strains may be able to penetrate the epithelium barrier and spread to 
extraintestinal sites, such as liver, gallbladder, pancreas, uterus and fetal tissues (135).  Once 
the intestines have been colonized, abortifacient Campylobacter spp. must breach the 
intestinal epithelium and induce bacteremia.  Bacteremia attributable to C. jejuni has been 
described (23,95,150), and the results of one study (134) indicated that certain strains of C. 
jejuni have enhanced ability to induce bacteremia.  Therefore, bacteremia is an essential 
factor for systemic infection, enabling the organism to reach the fetoplacental unit, where 
multiplication results in placentitis and eventually leads to abortion (35,130,133,135).  Less 
is known about the pathogenesis of C. jejuni infections that gain access to the vascular space 
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and cause systemic infection.   When a systemic C. jejuni infection occurs in an apparently 
healthy individual, the recovered isolate is likely to have features promoting persistence in 
the bloodstream that distinguish it from diarrheal C. jejuni strains (23).   
 
Epidemiology  
 C. jejuni resides in the intestinal tracts of many wild and domestic animals as a 
commensal organism.  The avian species are the most common hosts for Campylobacter 
probably because of their higher body temperature (129,132).   Campylobacter appears to 
permanently colonize the gastrointestinal tract of birds with few noticeable ill effects and 
only occasionally is diarrhea observed with Campylobacter infection in young animals (110).  
Shedding of Campylobacters by birds (very high Campylobacter carriage rates have been 
reported among geese and ducks (10,122), among others) causes contamination of 
waterways, and as Campylobacters can survive in water for weeks, open waters may then act 
as a source of infection for domestic animals (37).   
 A large number of published studies on the incidence of Campylobacter spp. in food 
animals confirm that these human pathogens are also commonly found in many types of food 
animals other than chicken, e.g., cattle, pigs, dairy cows, turkeys, duck or lamb (75).  The 
digestive tract of healthy cattle has been demonstrated to be a significant reservoir for a 
number of Campylobacter spp., with prevalence in cattle ranging from 0-80 % (9), while the 
prevalence in sheep is about 20% (164).  In addition, high prevalence in pigs has been 
reported (109).   
Recent studies performed by our group (128) made the observations that a highly 
pathogenic C. jejuni clone (clone SA) has become a persistently predominant cause of 
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Campylobacter-associated ovine abortions in the United States, suggesting that the clone is 
ecologically well adapted and pathologically hypervirulent in ruminants (107).  Also, clone 
SA was detected in healthy sheep and cattle, and abortion cases in cows and goats, indicating 
that the clone is present in the ruminants as both commensal and a pathogen.  The presence 
of C. jejuni clone SA in the bile of healthy sheep suggests that it may colonize the gall 
bladder, which would facilitate the persistence of clone SA in sheep.   
 The majority of Campylobacter infections in humans are sporadic and predominantly 
associated with poor handling of raw chicken or consumption of undercooked chicken 
(41,44,50).  Other risk factors include contact with house pets, exposure to farm animals, and 
the consumption of raw milk, untreated water, and undercooked beef, pork, and shellfish 
(21,44).  Outbreaks due to Campylobacter are most commonly associated with consumption 
of raw milk, contaminated surface water, and chicken meat (21,60,61).  Despite the 
prominent role of poultry in the transmission of campylobacteriosis, recent molecular 
epidemiological studies indicate that ruminants also contribute significantly to both sporadic 
cases and the outbreak of human infections via contaminated milk, water and produce 
(34,39,67,107).   
 
Treatment and resistance 
 As C. jejuni infection is usually self-limited, in most cases there is no rationale for 
antimicrobial treatment.  Supportive measures, such as fluid and electrolyte replacement, are 
the principal therapies for most patients with campylobacteriosis.  Antibiotic therapy, 
however, should be considered for individuals who have high fever, bloody diarrhea, 
prolonged infection, pregnancy, HIV or are immunocompromised.  Antibiotics, generally 
20 
 
macrolides, tetracycline and fluoroquinolones, are reserved for more severe cases.  However, 
the increasing resistance to fluoroquinolones, tetracycline and erythromycin of C. coli and C. 
jejuni strains, might compromise the efficacy of this treatment (1,4,47,55).   Currently, 
erythromycin is the drug of choice for most Campylobacter infections, because of its low 
cost, ease of administration, lack of serious toxicity, and narrow spectrum of activity (5).   
 Antibiotic resistance among Campylobacter has become a serious problem 
worldwide.  Fluoroquinolones have become less effective as resistance has increased 
dramatically (47).  Since antibiotics have been indiscriminately used in animal production for 
decades in order to control, prevent and treat infections, and enhance animal growth 
(45,76,125), there is strong evidence that supports the hypothesis that the unregulated use of 
antimicrobial agents in food animal production has led to the emergence and spread of 
antibiotic resistance among Campylobacter spp. (129).  Smith (136) demonstrated a 
significant increase in quinolone resistance among human Campylobacter isolates between 
1996 and 1998 that was temporally associated with the licensure of fluoroquinolones for use 
in poultry in the United States.   
 The tetracycline class of antibiotics (tetracycline, oxytetracycline, and 
chlortetracycline) is commonly used in the prevention and control of abortion storms 
associated with Campylobacter spp. in the United States (56); however, speculation from 
clinical veterinary practitioners has suggested an increasing ineffectiveness of these drugs in 
treating Campylobacter-associated abortions (128).  A recent study performed by Sahin et al. 
(128) determined the antimicrobial susceptibility patterns of C. jejuni isolates from sheep 
abortion to the drugs that are commonly used in food animal production; strikingly, the 
results demonstrated that 100% of the C. jejuni isolates associated with sheep abortions 
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across the U.S. were resistant to oxytetracycline, suggesting that this class of antibiotics is no 
longer effective in treating Campylobacter-induced abortion.   
 
Prevention 
 As the primary source of Campylobacter infection in humans is foodstuffs, 
particularly poultry, prevention should be aimed at reducing the infection level among 
poultry houses.  Installing hygienic barriers between the external and internal environments, 
such as controlling the entry of farm personnel, strict hygienic routines such as washing and 
sanitizing of hands, changing boots and coveralls before entering, have been shown to be 
effective, but these control measures are easily and often breached (129).  Reducing the level 
of Campylobacter during slaughter and preventing cross-contamination of carcasses is an 
ideal way to control human infection.  Public education programs emphasizing good hygiene 
and food preparation techniques are also important in the prevention of Campylobacter 
infection. 
 The use of antibiotics in food animal rearing has been hotly debated since 
speculations have suggested that this has given rise to antibiotic-resistant strains, severely 
limiting the efficacy of antibiotics in treating human disease (46,47,64,136,144).  However, 
the use of pre- and pro-biotics (i.e., complex polysaccharides and strains of lactic acid 
bacteria), competitive exclusion, application of bacteriocin-producing bacteria, and 
bacteriophages have shown some promise (129,140). 
 Vaccination against Campylobacter has been used to control sheep abortion 
worldwide.  Currently, there are at least two vaccines available in the United States used for 
protection against sheep abortions caused by Campylobacter; however their efficacy varies 
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widely.  It is likely that the strains incorporated in these formulations were those that were 
the most common species/serotypes at the time the vaccine was created.  Thus, new vaccines 
are necessary to account for the increasing role of C. jejuni in sheep abortions. 
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Abstract 
Campylobacter jejuni clone SA has emerged as the predominant cause of 
Campylobacter-associated ovine abortion in the U.S., and this clone is highly pathogenic in 
pregnant sheep and guinea pigs.  To induce abortion, orally ingested Campylobacter must be 
able to translocate across the intestinal epithelium and spread systemically.  To understand 
the pathogenic mechanisms and immune protection of C. jejuni-induced abortion, it is 
necessary to develop a cost-effective animal model to evaluate systemic infection induced by 
this pathogenic clone.  In this study, two different breeds of female mice (BALB/c and CD-1) 
were orally inoculated with C. jejuni IA3902, a clinical clone SA isolate whose complete 
genome sequence has been determined, to evaluate the induction of bacteremia and hepatic 
infection.  Our results revealed that CD-1 mice were more susceptible than BALB/c mice to 
infection by IA3902.  In CD-1 mice, C. jejuni IA3902 induced bacteremia and hepatic 
infection within 1 hour after oral inoculation, and bacteremia peaked at 8 and/or 12 hours 
after inoculation.  Compared with IA3902, the magnitude and duration of bacteremia and 
hepatic infection induced by C. jejuni strains NCTC 11168 and 81-176 were significantly 
less prominent, indicating that IA3902 is more virulent than the other strains tested with 
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regard to systemic spread.  Mutagenesis in IA3902 showed that the loss of the capsule 
(ΔkpsS) completely prevented the organism from causing bacteremia and hepatic infection, 
while the loss of pVir plasmid did not affect systemic spread.  These findings indicate that 
the CD-1 mouse model is suitable for examining critical steps of Campylobacter 
pathogenesis and identify the capsule as a key virulence factor of this pathogenic organism to 
induce bacteremia.   
 
Introduction 
Campylobacter species have been recognized as one of the most prominent causes of 
ovine abortion in the United States and worldwide, with an overall abortion rate of 5-50% in 
affected flocks (55).  A recent national study, NAHMS Sheep 2001, conducted by 
USDA/APHIS/Veterinary Services in collaboration with the American Sheep Industry 
Association, revealed that Campylobacter species ranked first among all infectious causes of 
abortion within the last 3 years of the study, with 53.7% of the reported cases confirmed by a 
veterinarian or diagnostic laboratory (62).   
Historically, C. fetus subsp. fetus accounted for the majority of the Campylobacter 
spp. associated with ovine abortion, however, we and others recently discovered a 
remarkable shift in the etiology of the disease (22,53).  Specifically, a highly virulent C. 
jejuni clone (clone SA for sheep abortion) has replaced C. fetus as the predominant cause of 
ovine abortion outbreaks in the U.S.  Considering the high genetic diversity in 
Campylobacter species and the strains responsible for sheep abortion in the U.S. prior to the 
predominance of the SA clone (1,44,57), this finding was quite surprising and indicates that 
clone SA has evolved to possess novel virulence traits and agricultural practices in sheep 
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production have favored the dominance of this hypervirulent clone.  The high virulence of 
clone SA in causing abortion was confirmed using a pregnant guinea pig model, in which the 
distinct abortifacient ability of the clone was shown compared with other C. jejuni strains 
(41).   
Campylobacter species usually live as commensals in the intestines and gall bladder 
of healthy sheep without causing clinical diseases (1,44,57).  However, highly virulent C. 
jejuni strains, such as the SA clone can cause systemic infections.  In susceptible pregnant 
ewes, initial ingestion of C. jejuni is believed to be followed by intestinal invasion and 
bacteremia with subsequent placentitis, fetal infection and abortion (55).  The ability of the 
organism to induce bacteremia is one of the key elements in the abortion process.  To 
facilitate bacteremia, C. jejuni must first invade the mucosal tissue of the intestinal tract, 
consequently surpassing the host immune responses in the blood long enough for bacteremia 
to spread systemically.  Clone SA is highly abortifacient in both sheep and the pregnant 
guinea pig model, and therefore, it must possess distinctive virulence characteristics enabling 
it to invade the host intestine and bloodstream.   
Despite these advancements in understanding Campylobacter pathogenesis and its 
obvious global importance, little is known about the molecular mechanisms of 
Campylobacter-associated abortion.  The lack of high-resolution, tractable and reproducible 
models for studying infection in vivo has clearly hampered progress (18).  An optimal animal 
model to study Campylobacter pathogenesis should comprise several features (70). 
Symptoms similar to those observed in abortion cases are required after oral administration 
of bacteria to animals.  Sheep are generally silent carriers and do not exhibit any symptoms 
of clinical disease.  Although the pregnant guinea pig model resembles Campylobacter-
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induced abortion in sheep (17), it is cost prohibitive (>$300 per animal), time consuming and 
cumbersome, and is not feasible for large-scale studies involving multiple experiments.  
Murine models of C. jejuni infection overcome some of these limitations, and therefore, are 
useful for assessing systemic infection.  These mouse models have been used to study 
colonization and/or virulence mechanisms and host responses (30,36,51,61,64), to screen 
natural isolates or laboratory strains carrying spontaneous or targeted mutations that are 
thought to affect colonization and/or virulence (11,28,40,42,50,63). Furthermore, bacteremia 
was a very common and consistent finding in several studies (8,12,45,48), suggesting the 
suitability of the mouse model for studying Campylobacter pathogenesis.  We hypothesize 
that mice are susceptible to the highly pathogenic clone SA and can provide a suitable model 
for investigation of systemic dissemination of pathogenic Campylobacter in infected animals.      
        
 Surface polysaccharides represent the predominant structures on bacterial cell 
surfaces, and they are often important in the interactions between pathogens, their hosts and 
the environment (24).  C. jejuni is now known to produce capsular polysaccharide (CPS) 
(19,34,46). CPS is one of the few known virulence factors of C. jejuni that are required for 
diarrheal disease in ferrets, chicken colonization, the adherence and invasion of human 
epithelial cells, serum resistance and surface charge (5,31).  Karlyshev et al. (33) have shown 
that site-specific insertional mutagenesis of polysaccharide transporter genes kpsM, kpsS or 
kpsC in several strains resulted in the loss of a high-molecular-weight glycan, providing 
isogenic mutant strains for evaluation the role of CPS in pathogenesis.  Despite these studies, 
the role of CPS in Campylobacter bacteremia and systemic infection has not been evaluated. 
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 The pVir plasmid has been recognized as a potential virulence factor in C. jejuni, 
because strains carrying this plasmid had an increased ability to invade INT 407 cells in vitro 
(4-6,69).  In addition, previous studies by others reported that pVir contributed to 
Campylobacter virulence in a ferret diarrheal disease model and was associated with bloody 
diarrhea in Campylobacter jejuni enteritis (4,60).   Although pVir is not exclusively 
associated with clone SA isolates, there is a possibility that pVir interacts with 
chromosomally encoded factors in clone SA in inducing sheep abortion.  We cured pVir (Q. 
Zhang laboratory, unpublished data) and reintroduced the plasmid back into the cured 
background to assess if the plasmid as a whole contributes to bacteremia in the mouse model, 
after determining that it is not required for abortion in the pregnant guinea pig model (Q. 
Zhang laboratory, unpublished data). 
In this study, we demonstrate that oral dosing of C. jejuni IA3902 (a clone SA isolate) 
into CD-1 mice leads to efficient establishment and reproducible bacteremia and systemic 
infection.  Since IA3902 is able to successfully induce bacteremia in our murine model it 
should prove sensitive enough to identify mechanisms necessary for producing bacteremia.  
Here we report that the loss of capsular expression in IA3902 hinders the ability of the 
isogenic mutant to produce bacteremia and/or systemic infection.  This work establishes a 
model system that can examine and identify molecular and genetic factors involved in 
Campylobacter-induced bacteremia.       
 
Materials and Methods 
Bacterial strains and growth conditions.  C. jejuni strain IA3902 is a clinical isolate 
originally isolated from an ovine abortion case described previously (53), and was the wild-
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type strain used in this study.  C. jejuni NCTC 11168 and 81-176 are both human isolates, 
non-abortifacient, sequenced and used as controls to assess the bacteremic properties of 
IA3902.  All C. jejuni strains were grown on Mueller-Hinton (MH) agar under microaerobic 
(5% oxygen, 10% carbon dioxide, and 85% nitrogen) conditions at 42°C for up to 48 h.  As 
needed for specific experiments, the culture medium was supplemented with Campylobacter 
selective (polymyxin B, rifampicin, trimethoprim, and cycloheximide) and supplemental 
(sodium pyruvate, sodium metabisulfite, and ferrous sulfate) growth media (Oxoid, 
Cambridge, England), kanamycin (50 µg/mL) or chloramphenicol (20 µg/mL).  C. jejuni 
strains used in this study are listed in Table 1.   
 
Mice.  Wild-type BALB/c (inbred) and CD-1 (outbred) female mice 8 to 10 weeks old were 
purchased from Charles River Laboratories (Wilmington, MA) and maintained by the 
Division of Laboratory Animal Resources at the College of Veterinary Medicine at Iowa 
State University.  The mice were housed for a minimum of two days before being used for 
experiments.  Following oral inoculation, mice were housed in groups of four or five in 
sterile polycarbonate microisolator cages with autoclaved bedding and provided with 
sterilized water and food ad libitum.     
 
Oral Challenge.  C. jejuni used for inoculations was recovered from freezer stocks (-80°C, 
20% glycerol), plated on selective medium and incubated for 48 h as described above.  
Bacterial cultures obtained from these plates were sub-passaged under the same conditions 
for 18 h.  Fresh cultures were harvested and suspended in MH broth, diluted to the desired 
concentration based on optical density, and subsequently confirmed by viable counts.  Each 
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mouse received 100 µl bacterial culture (approximately 10
8
 CFU) via oral gavage using a 
curved, ball-tipped, 18-gauge, 2-inch needle, under light sedation with 2% isoflurane as 
previously described (12).   
 
Quantitation of systemic infection.  Post inoculation 1, 8, 12, 24 and 48 h mice were 
anesthetized/euthanized via intraperitoneal (IP) injection of a ketamine/xylazine mixture.  
Fecal swabs were taken before challenge, and a non-inoculated control group (n=5) was 
sacrificed at the final time point (48 h) to confirm all mice were Campylobacter-free and that 
no cross contamination occurred.  Samples harvested for Campylobacter culture included 
cardiac blood and liver.  Cardiac blood was collected by use of a sterile tuberculin syringe 
with a 22-gauge needle and placed in blood collection tubes (0.5 mL Greiner Vacuette 
MiniCollect K3 EDTA, Fisher Scientific).  Within a couple of hours of sample collection, 
250 µL of undiluted blood and appropriate serial dilutions thereof were plated on selective 
medium and incubated for 48 h.  Liver tissues were placed in a separate sterile plastic bag 
(Whirl-Pak bags, Nasco, Fort Atkinson, WI), weighed, homogenized in sterile MH broth, 
serially diluted, plated on selective medium and incubated for 48 h.  C. jejuni recovery was 
expressed as Log10 CFU/ml or g of blood or liver.  Recovered isolates were subjected to PCR 
confirmation to assure that the source of infection was the oral inoculation but not 
environmental or cross contamination.     
 
Construction of a CPS mutant.  Construction of the CPS mutant was performed according 
to the previously reported method (29).  Briefly, a 1693bp region harboring kpsS (CJSA 
1344) was PCR-amplified with kpsS_F and kpsS_R primers (Table 2) and cloned into the 
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commercial vector pGEM-T (Promega, Madison, WI) to yield pGEM-T::kpsS.  The resulting 
amplicon and the pMW10 (67) plasmid, carrying aphA-3 gene, were digested with SwaI and 
ligated.  The suicide vector was delivered to C. jejuni IA3902 via natural transformation, and 
mutants were selected on MH agar plates containing kanamycin (50µg/mL).  ΔkpsS mutants 
were confirmed by PCR analysis and Alcian Blue staining.   
 
Alcian Blue staining for CPS.  Preparation of CPS samples and Alcian Blue staining were 
performed as previously described (35).  Wild-type and mutant C. jejuni cells were harvested 
following 24hr  growth on MH agar, weighed and solubilized in 300 µL of lysis buffer (2% 
sodium dodecyl sulfate, 4% 2-mercaptoethanol, 10% glycerol, 1 M Tris-HCL, pH 6.8 and 
10mg bromophenol blue) for 10 min at 100°C.  20 µL aliquots were taken and mixed with 
proteinase K (Sigma, St. Louis, MO) to a final concentration of 1 µg/µl and incubated at 
50°C for 1 h and fractionated by SDS-PAGE.  CPS was visualized with Alcian Blue staining 
(0.1% Alcian Blue dye, 40% ethanol, 5% acetic acid).   
 
Complementation of the kpsS mutant in trans.  Construction of the complementing 
plasmid for the kpsS mutant was based on a previously published study (25).  The entire kpsS 
gene was amplified from strain IA3902 by PCR using primers ST101_F and ST101_R (Table 
2).  The PCR product was digested with SacI and SacII and cloned into the plasmid construct 
pRY112-pABC (39,68) to generate pRY112-kpsS, in which the kpsS gene was fused to the 
promoter of cmeABC.  The constructed plasmid was confirmed by PCR.  For 
complementation, the shuttle plasmid pRY112-kpsS was introduced into the  ΔkpsS mutant 
by conjugation.  The complemented strain was isolated on MH agar containing 
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chloramphenicol (20µg/mL), and named ΔkpsS-comp.  PCR analysis and Alcian Blue 
staining were performed to confirm complementation.   
 
Statistical analysis.  Systemic infection results are expressed as the mean with error bars 
denoting the standard error of the mean (SEM).  Statistical analysis of systemic infection 
results was performed with the Student t test.  P values of less than 0.05 were considered 
statistically significant.  
 
Results 
Effect of mouse strain on systemic infection by C. jejuni.  Two mouse strains were 
challenged orally with 10
8
 CFU/mL of C. jejuni IA3902.  The outcome was measured at the 
ability of IA3902 to cause bacteremia and liver infection following 1, 8, 12 and 24 h post 
inoculation in BALB/c (inbred) and CD-1 (outbred) mice (Figure 1).  Susceptibility was 
noted in both strains, but CD-1 mice were significantly more susceptible (p < 0.05).  
Therefore, CD-1 mice were selected for subsequent experiments.   
Differences of Campylobacter jejuni strains in producing bacteremia in CD-1 mice.  To 
assess the ability of clone SA to induce bacteremia, separate groups of mice (n=5) were 
orally challenged with 10
8
 CFU C. jejuni IA3902, NCTC 11168 and 81-176, respectively. At 
1, 8, 12, 24 and 48 h after oral inoculation, cardiac blood and liver tissues were cultured for 
C. jejuni.  The ability to cause bacteremia and liver infection were used as measures of 
virulence.  Pathogenic ability varied as a function of strain and time (Figure 2); IA3902 was 
the most virulent (p < 0.05) with peak infection between 8 and 12 h post-infection (p.i.), and 
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NCTC 11168 was the least virulent with no observation of bacteremia or liver infection.  
Strain 81-176 caused only transient infection. 
The infected mice did not appear ill or show any clinical symptoms of infection.  
Animals challenged with IA3902 were bacteremic within 1 h after dosing.  The bacterial 
burden persisted through 48 h at which time the experiment was terminated.  Since the liver 
plays a potential role in clearing C. jejuni from the bloodstream, homogenized liver tissues 
were also cultured.  Quantitative cultures of IA3902 in the bloodstreams and the livers of the 
orally infected mice did not show any significant differences.  These results indicate that 
clone SA possesses a remarkably increased ability to induce bacteremia and liver infection in 
mice.   
 
Construction and confirmation of CPS mutants of Campylobacter jejuni IA3902.  To 
determine the role of C. jejuni IA3902 genes involved in inducing bacteremia, we selected 
the kpsS as a target gene to disrupt CPS.  The kpsS gene encodes an ABC transporter 
involved in capsule transport (33).  Many studies have been conducted investigating the role 
of C. jejuni CPS and its pathogenic properties.  While such studies have been useful for 
defining the general functions of the CPS, we decided to take advantage of the mutants in 
hand to embark on a comparative analysis of a mutated CPS and its specific aspects of 
IA3902 pathogenesis.  Thus, we conducted an insertional/deletion mutagenesis in kpsS of 
IA3902 in order to define the role of CPS in bacteremia using the mouse model developed.  
In each mutant strain, a portion of the sequence was replaced with aphA-3 (encoding 
kanamycin resistance) by double-crossover homologous recombination.  Loss of the CPS in 
the mutant was confirmed by Alcian Blue staining (Figure 3).  The CPS complemented strain 
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(ΔkpsS-comp) restored production of normal CPS (Figure 3).  The growth rate of the CPS 
mutant in MH broth was comparable to that of the wild-type (data not shown).  Both ΔkpsS 
and ΔkpsS-comp grew comparably on selective and nonselective agar plates to that of the 
wild-type (Table 4), and each exhibited wild-type motility (Table 3). 
 
Mouse model identifies a role for CPS in vivo.  We hypothesized that the loss of the CPS 
would make the ΔkpsS mutant less virulent than the wild-type, and unable to induce 
bacteremia and cause subsequent systemic infection.  To explore this, we tested the ΔkpsS 
mutant in the mouse model developed in this study.  Three groups of CD-1 mice (n=8/group) 
were orally challenged with ΔkpsS mutant, ΔkpsS-comp and wild-type IA3902 strains.   
At 1, 8 and 12 h  post inoculation (p.i.), cardiac blood and liver tissues were collected for 
CFU counts.  The ΔkpsS mutant exhibited a striking and statistically significant (p < 0.05) 
bacteremic defect evident from 1 h p.i. through 12 h p.i. (Figure 3A and C).  The 
complemented strain caused levels of bacteremia and liver infection similar in frequency and 
intensity to the wild-type strain. 
 
pVir plasmid as a whole does not contribute to bacteremia.  The pVir plasmid is present 
in some C. jejuni strains and carries a putative type IV secretion system, as well as other 
genes of unknown function.    Recently we cured pVir from the SA clone to determine if the 
plasmid itself contributes to Campylobacter abortion in the guinea pig model (Q. Zhang 
laboratory, unpublished data).  To further define the role of pVir, we decided to investigate if 
the plasmid as a whole contributes to bacteremia in the mouse model.  Although pVir-cured 
strain had significantly less level of bacteremia and liver infection at 8 h p.i., it showed 
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comparable levels of systemic infection to that of the wild-type strain at 1 h and 12 h p.i. 
(Figure 3B and D).  This finding indicated that pVir plasmid as a whole does not seem to 
contribute significantly to the overall process of bacteremia and liver infection caused by C. 
jejuni in our mouse model.          
 
Discussion 
 C. jejuni is a major cause of sheep abortion worldwide, imposing a significant 
economic burden for producers.  Over the past several years extensive effort has been 
directed toward the development of in vivo model systems suitable to study Campylobacter 
pathogenesis.  However, progress toward understanding the pathogenic mechanisms of 
Campylobacter has been hampered by the paucity of high-resolution experimental systems 
for studying infection in vivo (70).  These have included studies of primates (9,23,52), dogs 
(49), pigs (3), chickens (26), ferrets (10), and guinea pigs (17,59).  The large number of 
models speaks to the difficulties encountered in identifying a system that is sufficiently 
robust to meet research requirements.  An optimal animal model for characterizing 
Campylobacter infection should be readily available and reasonable in cost, easy to maintain 
and handle, and it should able to reproduce the pathology associated with ovine abortion.   
 Our research group has recently investigated the high virulence of C. jejuni clone SA 
in inducing abortion, and we evaluated its virulence in pregnant guinea pigs (17).  Guinea 
pigs represent a well-established model to study Campylobacter-induced abortion (21,58,59), 
because they are susceptible to Campylobacter and the induced disease is similar to that seen 
in sheep.  Although the model is appropriate for investigating Campylobacter-induced 
abortion, it is cost prohibitive (>$300 per animal), time consuming and cumbersome, and is 
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not feasible for large-scale studies involving multiple experiments.  In order to continue our 
efforts of understanding pathogenesis in detail, an efficient animal model is needed to assess 
the critical steps involved in C. jejuni abortion.  Studies have established mouse disease 
models in which no grossly observable disease occurs following oral challenge, yet 
dissemination of bacteria to the blood is commonly seen (7).  In this study, we determined 
the unique ability of C. jejuni clone SA to produce bacteremia in a mouse model compared 
with other C. jejuni isolates, NCTC 11168 and 81-176.  To our knowledge, this work is the 
first comprehensive study that examines the molecular and genetic factors involved in C. 
jejuni-induced bacteremia using a mouse model following oral challenge. 
To develop a reproducible and widely applicable murine model to study 
Campylobacter-induced abortion we chose to use IA3902 an isolate of clone SA, because its 
pathogenicity has been established and its genome is fully sequenced.  We also included non-
abortifacient C. jejuni strains NCTC11168 and 81-176, originally derived from human 
clinical isolates, because both strains are also whole genome sequenced and widely used in 
many research laboratories across the world.  
In our preliminary experiments, we determined which mouse strain was more 
susceptible to systemic infection by clone SA after oral inoculation, and our results clearly 
demonstrate a discernible difference between the two strains.   We initially inoculated 
commercially supplied BALB/c and CD-1 mouse strains.  CD-1 mice and C. jejuni IA3902 
proved to be the preferred host-parasite combination for studies of pathogenesis, opposed to 
BALB/c mice, which presented low vulnerability to the organism (Figure 1).  CD-1 mice 
remained persistently bacteremic at a high level until they were euthanized 24h after 
inoculation.  Our inability to efficiently infect  BALB/c mice with IA3902 could be 
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influenced by different factors such as gut microflora, rearing practices or simply the genetic 
makeup of the mouse (12).  With the CD-1 species, we have consistently found that 
pretreatment with antibiotics is not necessary, in contrast to previous studies (30).  With these 
considerations in mind, we used CD-1 mice.   
The pathogenesis of Campylobacter spp that induce abortion when acquired by a 
nonvenereal route of transmission entails oral exposure, intestinal colonization, bacterial 
invasion, bacteremia, and infection of the fetoplacental unit (20,54-56).  The specific 
mechanisms of bacteremic Campylobacter are not well understood.  However, the known 
depression of cell-mediated immunity during pregnancy may be relevant to the development 
of systemic Campylobacter infection and septic abortion (54).  In the past, Campylobacter 
fetus subsp. fetus was recognized primarily as a cause of systemic illnesses (14), whereas 
Campylobacter jejuni was predominantly recognized as a cause of diarrheal illnesses (66).  
Blaser et al. (16) reported that C. jejuni strains are usually susceptible to the complement-
mediated bactericidal activity present in normal human serum, whereas C. fetus strains 
usually are resistant.  However, bacteremia attributable to C. jejuni has been described 
(13,38,65), while one study indicated that certain strains of C. jejuni have an enhanced ability 
to induce bacteremia.  Additionally, acute hepatitis has been a result of bacteremia triggered 
by C. jejuni in humans (37).  In the remainder of the studies, there were no demonstrable 
clinical signs of infection, despite the bacterial load recovered from the blood and liver 
tissues.  C. jejuni IA3902 was remarkably capable in its ability to induce bacteremia 
following oral inoculation (Figure 3A).  Whereas, 81-176 caused minor bacteremia within 
the first hour, but was unable to survive through 24h in substantial numbers, and 11168 did 
not induce systemic infection (Figure 3A and B).  The fact that both blood and liver tissues 
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could be readily infected with IA3902 indicates that the mouse model is suitable for 
assessing the systemic infection by C. jejuni.  In addition, these results suggest that IA3902 
acquired specific traits similar to C. fetus when the shift in disease occurred, therefore, 
allowing it to resist complement-mediated bactericidal activity, and cause bacteremia.     
Analysis of the CPS of the kpsS mutant by Alcian Blue staining showed that the 
mutant did not express a capsule.  As the CPS mutant still expressed complete LOS 
molecules (Figure 3), this confirms previous reports that the capsule of C. jejuni is expressed 
independently of the LOS molecule (2). 
This study provides the first evidence of a role for the C. jejuni clone CPS in 
pathogenesis.  Several in vitro studies have indicated that a surface array protein (a capsule-
like protein structure) in wild-type C. fetus strains plays a critical role in the organism's 
ability to resist both the complement-mediated bactericidal activity (C3b binding) in normal 
human serum and phagocytosis by neutrophils (15,16,43).  S-plus C. fetus strains can 
apparently penetrate the intestinal wall and produce bacteremia lasting 48-120 h after oral 
challenge (47).  Similar experiments performed on C. jejuni 81-176 demonstrated a role for 
the capsule in serum resistance (5), while more recent studies have revealed that the CPS is 
required for virulence, and mutations within the kps gene cluster, those that are responsible 
for transferring the CPS to the outer membrane, showed reduced adherence and invasion of 
intestinal epithelial cells, and reduced virulence in the ferret model (5).  Since the CPS locus 
of Campylobacter is under phase variation, shows high genetic diversity, has the potential to 
mimic host cell antigens, the ability to resist innate mechanisms such as phagocytosis and 
complement-mediated killing (32) and the fact that clone SA seems to have a distinct CPS 
structure (as determined by comparative phenotypic and genomic analyses; unpublished 
52 
 
data), we investigated its role in induction of systemic infection using the mouse model 
developed in this study.  Our observation of the ΔkpsS mutant in vivo clearly coincides with 
similar studies confirming C. jejuni clone SA CPS is an important bacterial component 
contributing to bacteremia.  The mechanism for this penetration has not been determined, but 
it is clearly rapid in onset.  The inability of the ΔkpsS mutant to induce bacteremia highlights 
the utility of mouse model to assess pathogenesis.  Our findings also suggest that the CPS as 
a whole or an individual component of the CPS contributes to bacteremia similarly to the S-
proteins of C. fetus.  Therefore, the CPS of clone SA must enable the organism to resist 
complement-mediated activity.  This in vivo study raises an important question relating to the 
mechanism by which encapsulated C. jejuni clone SA causes disease, how does the CPS 
enable clone SA to penetrate the intestinal wall and cause systemic infection. 
Finally, our mouse model measured the ability of pVir-cured IA3902 to induce 
bacteremia, and assess if the plasmid plays a role in the induction of systemic infection.  Our 
findings indicated that the pVir plasmid as a whole does not seem to contribute significantly 
to bacteremia or liver infection (Figure 3B and D).  Furthermore, it provides proof that the 
mouse model is efficient and provides a solid foundation for us to delineate key pathogenic 
properties associated with clone SA in an inexpensive way.    
Collectively, this work has yielded a cost-effective and tractable model system in 
which critical steps in the pathogenesis of Campylobacter-associated abortion can be readily 
assessed, and provided the first direct evidence for a role of the C. jejuni IA3902 CPS in 
virulence.  Besides the future promise of advancing our knowledge of Campylobacter 
pathogenesis, our murine model can potentially identify novel candidates for the 
development of protective vaccines against Campylobacter abortion in sheep.   
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Table 1. C. jejuni strains used in this study 
Strain or Plasmid Description
a
 Reference 
Strain   
C. jejuni   
IA3902 Wild type (53) 
ΔkpsS mutant IA3902 derivative kpsS:: kanr This study 
ΔkpsS – comp ΔkpsS complemented with pRY112-ΔkpsS – comp This study 
81-176 Wild type strain, invasive diarrheal isolate (27) 
NCTC 11168 Wild type strain, non-abortifacient diarrheal isolate (46) 
Plasmids   
pGEM-T   E. coli cloning vector (Promega) 
pGEM-T-kpsS pGEM-T containing full-length kpsS, kan
r
 (29) 
pMW10 E. coli-C. jejuni shuttle vector with promoterless E. coli lac Z gene, kan
r
 (67) 
pRY112 E. coli-C. jejuni shuttle vector, cat
r
 (68) 
pRY112- ΔkpsS – comp pRY112 containing the promoter region of cmeABC and full-length kpsS  This study 
a
 kan
r
 confers kanamycin resistance; cat
r
 confers chloramphenicol resistance. 
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Table 2.  PCR primers used in this study. 
Primers Sequence (5’ to 3’)a 
kpsS_F GCT CAA GTT GAA GAT GAT GCT TCG ATG AT 
kpsS_R CAT ACC AAA ACA GGA TTG GGT TTA TAA GCA TGA 
ST101_F      TAG CCG CGG AAA CTT TTA TGC TTA GAA AAA T 
ST101_R CTA GAG CTC TTA GGA TCA TAT CCT GCT ATA T 
a 
The underlined sequences in the primers indicate the restriction sites for SacI (GAGCTC) and SacII 
(CCGCGG).  
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Figure 1.  Susceptibilities of selected strains of mice to oral challenge with IA3902 (10
8
 CFU).  Five 
CD-1 and 5 BALB/c mice were infected and were necropsied at the indicated hour post-inoculation.  
Bacteremia (Figure 1A) and liver infection (Figure 1B) was determined as described in materials and 
methods.  Each bar represents the log10 CFU per ml of blood (mean ± SEM) in different strains of 
mice.  *p < 0.05 is statistically significant.   
‡
liver tissues were only collected at 8 and 12 h p.i. for BALB/c mice, but CD-1 mice liver tissues were 
collected at 1, 8, 12 and 24 h p.i.. 
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Figure 2.  Quantitation of systemic infection by IA3902, 81-176 and NCTC 11168 in CD-1 mice.  
Mice were orally challenged 10
8
 CFU.  At each time point, 5 mice were sacrificed and the number of 
C. jejuni in A) cardiac blood and B) liver tissue was determined.  Each bar represents the log10 CFU 
per ml of blood or liver (mean ± SEM).  *p < 0.05 is statistically significant.  
‡
Data was collected in 
different trials; all trials were performed under the same conditions 
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Figure 3. Analysis of capsule expression of C. jejuni IA3902 with Alcian Blue staining. 1) wild-type 
IA3902 2) capsule mutant (ΔkpsS) and 3) complemented mutant (ΔkpsS-comp)  
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Table 3.  Motility assay  
 
Fresh bacterial culture grown < 24h was harvested and diluted with MH broth to the desired optical 
density.  5µl of culture was stab-inoculated into motility agar plates and incubated for 48 h under 
standard conditions for Campylobacter.  The ΔkpsS mutant and   ΔkpsS – comp retained the wild-type 
level of motility.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain 
Diameter (mm) 
(mean ± SEM) 
IA3902 78±0.58 
ΔkpsS mutant 80±0.33 
ΔkpsS – comp 80±0.88 
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Table 4.  Ability to grow on selective media 
Strain 
Log10 CFU/mL  
(mean ± SEM) 
MH growth MH + SS 
growth
a
 
IA3902 1.7±0.060 1.9±0.044 
ΔkpsS mutant 1.7±0.090 1.6± 0.15 
ΔkpsS – comp 1.4±0.060 1.4±0.18 
a
 SS denotes Campylobacter selective and growth supplements media.   
Fresh bacterial culture grown 18 h was harvested and diluted with MH broth to the desired 
concentration based on optical density, followed by serial dilutions, plated on MH agar plates or 
MH+SS agar plates and incubated for 48 h under microaerobic conditions.  
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Figure 4.  Effect of CPS (A, C) and pVir (B, D) on systemic infection of mice by C. jejuni.  CD-1 
mice (n=8/group) were challenged with 10
8
 CFU via gastric gavage of either wild-type IA3902, 
ΔkpsS, ΔkpsS-comp or pVir mutant and CFUs were determined post-infection at different time points.  
Each bar represents the log10 CFU per ml of blood or liver (mean ± SEM).  *p < 0.05 is statistically 
significant.  (Data was collected in different trials; all trials were performed under the same 
conditions) 
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CHAPTER 3.  GENERAL CONCLUSION 
 
Campylobacter infection is one of the major causes of ovine abortions worldwide.  
Our work recently demonstrated the emergence of a predominant C. jejuni clone SA 
associated with sheep abortion in the United States.  In addition to causing sheep abortion, C. 
jejuni is among one of the leading causes of bacterial foodborne disease in developed 
countries.  However, as a zoonotic pathogen, little is known about the pathogenic 
mechanisms and the factors that influence the emergence and transmission of this highly 
pathogenic clone.  Therefore, understanding the nature, regulation, and mechanisms of action 
are indispensable for prevention and treatment of clone SA among sheep and controlling the 
transmission to humans. 
In this study, we developed a mouse model that is suitable for assessing bacteremia, a 
key element in Campylobacter-associated abortion and revealed genetic mechanism(s) that 
contribute to bacteremia.    
Our results indicated that clone SA is highly pathogenic in orally challenged CD-1 
female mice and has the ability to disseminate quickly and induce bacteremia.  In contrast, 
the non-abortifacient C. jejuni strain NCTC 11168 and C. jejuni 81-176 were incapable of 
producing bacteremia or produced substantially lower levels of bacteremia, respectively.  
These findings clearly indicate that the SA clone has acquired unique virulence properties, 
similar to those of C. fetus allowing it to resist complement-mediated bactericidal activity, in 
addition, this mouse model will provide us with the appropriate means to investigate how 
pathogenic Campylobacter cause systemic infection in infected animals.   
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Generating an insertional mutation in the kpsS gene, a capsule transporter protein, 
completely knocked out the expression of the CPS in C. jejuni IA3902, as indicated by 
Alcian Blue staining, while complementation fully restored the expression of the CPS.  Oral 
inoculation of CD-1 mice with ΔkpsS IA3902 mutant strain did not induce bacteremia, 
identifying CPS a major virulence factor of the SA clone. These findings suggest that clone 
SA has potentially acquired CPS structures similar to the surface layer proteins of C. fetus, 
which have historically been associated with bacteremia and systemic infection.  Despite its 
perceived virulence potential, the pVir plasmid, that is not unique to clone SA, was not found 
to contribute significantly to bacteremia, suggesting that pVir is not a major factors involved 
in producing systemic infection in our mouse model. 
Together, these results will advance our understanding of the pathogenic mechanisms 
involved in systemic infection due to Campylobacter, allow us to investigate more genetic 
factors that may contribute to bacteremia and will aid in the development of means to control 
this important disease in animals.           
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